USTEKINUMAB

ustekinumab 90 mg/mL injection, 1 mL syringe

USTEKINUMAB (14934B)

ustekinumab 90 mg/mL injection, 1 mL syringe
14934B
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe Crohn disease
Treatment phase: Initial 1 (new patient)

Restriction

Indication: Severe Crohn disease
Treatment phase: Initial 2 (change or recommencement of treatment after a break in targeted therapy of less than 12 months)

Restriction

Indication: Severe Crohn disease
Treatment phase: Initial 3 (recommencement of treatment after a break in targeted therapy of more than 12 months)

Restriction

Indication: Severe Crohn disease
Treatment phase: Transitioning from non-PBS-subsidised therapy that was commenced as a paediatric patient

Restriction

Indication: Severe Crohn disease
Treatment phase: Balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $986.28 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Steqeyma
Wezlana